相关临床试验
95
14 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1450
进行中（未招募）
4
4.2%
已完成
48
50.5%
Enrolling By Invitation
3
3.2%
尚未招募
7
7.4%
招募中
17
17.9%
终止
3
3.2%
Unknown
11
11.6%
撤回
2
2.1%
暂无批准数据
- Researchers reviewed 77 meta-analyses spanning 116 different bipolar disorder treatments to identify the most effective interventions across age groups and mood phases. - The team created EBI-BD, an open-access web platform presenting each treatment's impact, side effects, and strength of evidence to support shared decision-making. - For bipolar depression, effective adult treatments include cariprazine, fluoxetine, and lurasidone, while lurasidone and olanzapine with fluoxetine were effective in children and teenagers. - The review's results have already been used to update CANMAT and International Society for Bipolar Disorders (ISBD) treatment guidelines.
- A University of Barcelona study reveals that tumor-associated fibroblasts drive the divergent responses to anti-angiogenic therapy between lung adenocarcinoma and squamous cell carcinoma. - Adenocarcinoma exhibits active angiogenesis supported by fibroblast-driven synergy between VEGF and TIMP-1, while squamous carcinoma shows inefficient vessel formation and a more hypoxic, acidic environment. - The findings suggest that squamous cell carcinoma's historical exclusion from combined immunotherapy and anti-angiogenic strategies may be explained by these microenvironmental differences. - Researchers propose using biomarkers such as TIMP-1 for patient stratification and developing subtype-specific therapies targeting distinct pro-angiogenic pathways or tumor hypoxia.
- Researchers have developed a functional classification system for CTNNB1 mutations that can predict immunotherapy response in hepatocellular carcinoma patients. - The study analyzed 342 genetic variants and classified mutations as "strong" or "weak" based on their activation of the WNT/β-catenin pathway using CRISPR-based genome editing. - Strong mutations create immunosuppressive environments resistant to therapy, while weak mutations allow immune cell infiltration and better treatment response. - The classification was validated in 124 patient samples and has implications for precision medicine approaches in liver cancer and other solid tumors.
- REVEAL GENOMICS presented seven studies at SABCS 2025 analyzing over 1,300 tumor samples, showcasing major advances in precision oncology for breast cancer patients. - The company's newly developed HER2DX CNS Progression Score demonstrated strong risk stratification ability, with 3-year CNS progression rates of 39.2% in high-risk versus 4.3% in low-risk groups. - Multiple validation studies confirmed the superior predictive performance of HER2DX genomic scores over traditional biomarkers like tumor-infiltrating lymphocytes across different breast cancer subtypes. - The DEFINITIVE trial showed 94.3% success rate for HER2DX testing with 7-day median turnaround time, supporting real-time genomic testing integration in clinical practice.
- The European Medicines Agency has designated allopurinol as the first orphan drug for Marfan syndrome, a rare connective tissue disease affecting approximately 7 in 100,000 people in the European Union. - Researchers from the University of Barcelona, IDIBAPS, and CIBERER have demonstrated allopurinol's potential to halt and prevent aortic aneurysms in animal models, with international clinical trials in patients planned for the future. - This repurposing of allopurinol, currently used for gout treatment, represents a significant advancement for Marfan syndrome patients who currently have no curative options beyond limited palliative treatments and high-risk surgical interventions.
- A novel combination of radiation therapy with durvalumab and tremelimumab immunotherapy achieved a 93% complete response rate in muscle-invasive bladder cancer patients, offering a promising bladder-preserving alternative. - The IMMUNOPRESERVE trial demonstrated strong efficacy with 30 out of 32 patients maintaining their bladders after a median follow-up of 27 months, with 84% two-year overall survival rate. - The treatment regimen showed manageable safety profile with 31% grade 3-4 adverse events, presenting a potential alternative to radical cystectomy for eligible patients.
